Red cell lipid peroxidation and antioxidant system in haemodialysed patients: Influence of recombinant human erythropoietin (r-HuEPO) treatment

被引：17

作者：

Boran M. ^{[1
]}

Küçükaksu C. ^{[2
]}

Balk M. ^{[2
]}

Çetin S. ^{[1
]}

机构：

[1] Dept. Haemodialysis and Transplant., Turkiye Yuksek Ihtisas Hosp., Ankara

[2] Department of Biochemistry, Turkiye Yuksek Ihtisas Hosp., Ankara

来源：

International Urology and Nephrology | 1998年 / 30卷 / 4期

关键词：

International Urology; Decrease Lipid Peroxidation; Reduce Glutathione Content; Erythrocyte Superoxide Dismutase; Haemodialysed Patient;

D O I：

10.1007/BF02550233

中图分类号：

学科分类号：

摘要：

In order to determine the role of correcting anaemia with r-HuEPO on susceptibility of red cell to lipid peroxidation, 15 patients on maintenance haemodialysis treated with r-HuEPO for at least one year (group I), 15 patients on maintenance haemodialysis without r-HuEPO (group II) and 30 persons as a control group (group III) were included in the study. We measured etythrocyte superoxide dismutase (e-SOD), erythrocyte catalase (e- CAT) activities, plasma malonyldialdehyde (p-MDA) and serum vitamin E levels in all patients. The healthy controls (group III) had significantly lower levels of p-MDA in comparison to those measured in haemodialysed patients (groups I-II) (p<0.0001). e-SOD activity in group III was significantly higher than in groups I and II, respectively (p<0.0001 and p<0.00001), and e- SOD activity was significantly lower in group II than in group I (p<0.0001). e-CAT activity in group III was higher than in groups I and II, respectively (p<0.0001 and p<0.00001) and it was significantly lower in group II than in group I (p<0.0001). Vitamin E concentration in group III was lower than in group I and group II, respectively (p<0.0001 and p<0.0001). But there is no difference between groups I and II. This study suggests that r-HuEPO therapy improves anaemia by decreasing lipid peroxidation and increasing antioxidant activity.

引用

页码：507 / 512

页数：5

共 25 条

[1]

Eschbach, J.W., Adamson, J.M., Anemia of end stage renal disease (1985) Kidney Int., 28, p. 1

[2]

Coro, C.S., Brown, S., Miller, O., Murray, T., Ersleu, A.J., Erythropoietin levels in uremic nephric and anephric patients (1979) J. Lab. Clin. Med., 93, p. 449

[3]

Yawata, Y., Jacop, H.S., Abnormal red cell metabolism in patients with chronic uremia: Nature of the defect and its persistence despite adequate hemolysis (1975) Blood, 45, p. 231

[4]

Eaton, J.W., Leida, M.N., Hemolysis in chronic renal failure (1985) Semin. Nephrol., 5, p. 133

[5]

Yawata, Y., Howe, R., Jacop, H.S., Abnormal red cell metabolism causing hemolysis in uremia: A defect potentiated by tap water hemodialysis (1973) Ann. Intern. Med., 79, p. 362

[6]

Trznadel, K., Pawlicki, L., Kedziora, J., Luciak, M., Blaszczyk, J., Buczynski, A., Superoxide anion generation, erythrocyte superoxide dismutase activity and lipid peroxidation during hemoperfusion and hemodialysis in chronic uremic patients (1989) Free Radic. Biol. Med., 6, p. 393

[7]

Kiskore, B.K., Gejya, F., Arakawa, M., Lipid peroxidation in uremia: Malonyldialdehyde, a putative toxin (1983) IRCS Med. Sci., 11, p. 750

[8]

Luciak, M., Tchorzewski, H., Trznadel, K., Release of neutrophil granule factors during early period of hemodialysis: A possible cause of hemodialysis neutropenia (1984) Nephron, 37, p. 30

[9]

Seth, R.K., Saini, A.S., Aggarwal, S.K., Glutathione peroxidase activity and reduced glutathione content in erythrocytes of patients with chronic renal failure (1985) Scand. J. Haematol., 35, p. 201

[10]

Giardini, O., Taccone-Gallucci, M., Lubrano, R., Ricciardi-Tenore, G., Bandino, D., Silvi, I., Ruberto, U., Casciani, C.U., Evidence of red blood cell membrane lipid peroxidation in hemodialysis patients (1984) Nephron, 36, p. 235

← 1 2 3 →